Publications

Ceger P, Choksi N, Hamm J, Truax J, Daniel A, Allen D, et al. Development of a curated database of in vivo developmental toxicity data. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Buerger AN, Schmidt J, Paixao C, Tiblier A, Martyniuk CJ, Bisesi JH. Does oral exposure to phthalates alter obesity related transcriptional networks in the gastrointestinal system through PPARα? Society of Toxicology Meeting, 2017.

Buerger AN, Schmidt J, Martyniuk CJ, Bisesi JH. Host-microbiome responses to DEHP exposure: A multigenerational obesity study in Danio rerio. Society of Environmental Toxicology and Chemistry North America Meeting, 2017.

Lynch M, Brown L, Chiger A. Case studies for neurotoxic chemicals. Presentation to Society for Risk Analysis, San Diego, CA, 2017.

Morgan SJ, Couch J, Guzzie-Peck P, Keller DA, Kemper R, Otieno MA, Schulingkamp RJ, Jones TW. 2017. Regulatory forum opinion piece: Use and utility of animal models of disease for nonclinical safety assessment: A pharmaceutical industry survey. Toxicol Pathol 45(3):372–380, doi: 10.1177/0192623317701004.

Prescott JS, Andrews PA, Baker RW, Bogdanffy MS, Fields FO, Keller DA, Lapadula DM, Mahoney NM, Paul DE, Platz SJ, Reese DM, Stoch SA, DeGeorge JJ. 2017. Evaluation of therapeutics for advanced-stage heart failure and other severely-debilitating or life-threatening diseases. Clin Pharmacol Ther 102(2):219–227, doi: 10.1002/cpt.730.

Ewart L, Fabre K, Chakilam A, Dragan Y, Duignan DB, Eswaraka J, Gan J, Guzzie-Peck P, Otieno M, Jeong CG, Keller DA, de Morais SM, Phillips JA, Proctor W, Sura R, Van Vleet T, Watson D, Will Y, Tagle D, Berridge B. 2017. Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective. Exp Biol Med (Maywood) 242(16):1579–1585, doi: 10.1177/1535370217715441.

Monticello TM, Jones TW, Dambach DM, Potter DM, Bolt MW, Liu M, Keller DA, Hart TK, Kadambi VJ. 2017. Current nonclinical testing paradigm enables safe entry to first-in-human clinical trials: The IQ consortium nonclinical to clinical translational database. Toxicol Appl Pharmacol 334:100–109, doi: 10.1016/j.taap.2017.09.006.

Frankenfeld CL. Human gut microbiome and health. University of Maryland, Maryland Institute of Applied Environmental Health, May 5, 2017.

Stephenson CJ, Rossheim ME, Frankenfeld CL, Boncy J, Okech BO, von Fricken ME. Association between bedtime and malaria exposure in the Sud-Est and Ouest Departments of Haiti. Poster presentation to American Public Health Association, 2017.

Frankenfeld CL. 2017. Cardiometabolic risk and gut microbial phytoestrogen metabolite phenotypes. Mol Nutr Food Res 61(1):1500900; doi: 10.1002/mnfr.201500900.

Miller LM, Lampe JW, Newton KM, Gundersen G, Fuller S, Reed SD, Frankenfeld CL. 2017. Being overweight or obese is associated with harboring a gut microbial community not capable of metabolizing the soy isoflavone daidzein to O-desmethylangolensin in soy-consuming peri- and post-menopausal women. Maturitas 99:37–42, https://doi.org/10.1016/j.maturitas.2017.02.006.

Wallace TC, Frankenfeld CL. 2017. Dietary protein intake above the current RDA and bone health: A systematic review and meta-analysis. J Am Coll Nutr 36:481–496, https://doi.org/10.1080/07315724.2017.1322924.

Stephenson CJ, Rossheim ME, Frankenfeld CL, Boncy J, Okech BO, von Fricken ME. 2017. Cross-sectional analysis of the association between bedtime and malaria exposure in the Ouest and Sud-Est Departments of Haiti. Acta Tropica 176:188–191, https://doi.org/10.1016/j.actatropica.2017.08.011.

Frankenfeld CL. 2017. Trends in employer postings for epidemiology jobs: An analysis of publichealthjobs.net data from 2003-2016. Ann Epidemiol 27:553–557, https://doi.org/10.1016/j.annepidem.2017.08.007.

Buerger AN, Howe K, Jacquart E, Chandler M, Culley T, Evans C, et al. 2015. Risk assessments for invasive plants: A Midwestern US comparison. Invas Plant Sci Manage 9(1):41–54; doi: 10.1614/IPSM-D-15-00018.1.

Wirbisky SE, Freeman JL. 2017. Atrazine exposure elicits copy number alterations in the zebrafish genome. Comp Biochem Physiol C Toxicol Pharmacol 194:1–8.

Thompson CM, Wolf, JC, McCoy A, Suh M, Proctor DM, Kirman CR, Haws LC, Harris MA. 2017. Comparison of toxicity and recovery in the duodenum of B6C3F1 mice following treatment with intestinal carcinogens captan, folpet, and hexavalent chromium. Toxicol Pathol 45(8):1091–1101; doi: 10.1177/019262331yy4324.

Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genet Toxicol Environ Mutagen 800-801(April):28-34; doi: 10.1016/j.mrgentox.2016.01.008.

Cui Y, Li J, Weng L, Wirbisky SE, Freeman JL, Liu J, Liu Q, Yuan X, Irudayaraj J. 2016. Regulatory landscape and clinical implication of MBD3 in human malignant glioma. Oncotarget 7(49):81698–81714; doi: 10.18632/oncotarget.13173.